Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03336619 · ClinicalTrials.gov registry record · Phase 3
A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza
A Phase 3 study, sponsored by Romark Laboratories L.C..
- Completed
- Registry status
- Phase 3
- Development phase
- 1,030
- Enrollment target
NCT03336619 is a Phase 3 study that has completed, run by Romark Laboratories L.C.. The registered enrollment target is 1,030 participants.
The verdict
NCT03336619, a Phase 3 study, has completed, sponsored by Romark Laboratories L.C..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,030 participants
- Enrollment target
Study Summary
Trial to evaluate efficacy and safety of nitazoxanide (NTZ) in the treatment of uncomplicated influenza.
Interventions
- DRUG Placebo
- DRUG Nitazoxanide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,030 participants |
| Start Date | 2018-01-17 |
| Est. Completion | 2019-04-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03336619
The ClinicalTrials.gov registry entry for NCT03336619 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,030 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Romark Laboratories L.C., which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03336619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03336619 about?
NCT03336619 is a clinical study titled "A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza". Trial to evaluate efficacy and safety of nitazoxanide (NTZ) in the treatment of uncomplicated influenza.
What is the current status of trial NCT03336619?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,030 participants. The study started on 2018-01-17. Estimated completion is 2019-04-17.
What interventions are being tested in trial NCT03336619?
The interventions under investigation include: Placebo (DRUG), Nitazoxanide (DRUG).
Who is sponsoring clinical trial NCT03336619?
This trial is sponsored by Romark Laboratories L.C., which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.